To assess the toxicity profile and determine the maximum tolerated dose (MTD), if possible,
of S-1153 administered orally 3 times daily for 14 days. To investigate the clinical
pharmacokinetic parameters for S-1153. To assess anti-HIV activity associated with S-1153
administration through evaluation of CD4 and viral load measurements.
Two separate schedules of S-1153 are administered on this study: single dose (2 dose
levels/cohorts) and repeated dose administration over 14 days (escalation through 4 dose
levels/cohorts). All doses are determined by body weight.
Single-dose study (Cohort 1):
(4 patients) low-dose po, following a standardized morning meal. (4 patients) low-dose po,
Single-dose study (Cohort 2), administered during the first 3 levels of the repeated dose
study and prior to the initiation of the 4th repeated dose level:
(4 patients): intermediate-dose po, following a standardized morning meal. (4 patients):
intermediate-dose po, fasted. Following treatment with S-1153, all single-dose patients
(Cohorts 1and 2) are observed for 21 days.
Repeated dose (escalation) study:
All doses are administered for 14 days. Three patients are entered at the starting dose of
S-1153. In the absence of dose-limiting toxicity (DLT), subsequent 3-patient cohorts are
entered at 3 escalating doses.
The last patient at any given dose level must be observed for 21 days prior to entry of
patient at the next dose. If 1 of the initial 3 patients experiences DLT at a given level, 3
additional patients will be added at that dose; if no additional toxicity occurs, escalation
resumes. If 2 or more patients at a given dose exhibit DLT, the previous dose is declared
the maximum tolerated dose (MTD) and 3 additional patients (6 total) are treated at that
1. Required for patients with CD4 cell count lower than 200:
- PCP prophylaxis with aerosolized pentamidine, trimethoprim/sulfamethoxazole, mepron,
- Continuation on an approved antiretroviral agent other than non-nucleoside reverse
transcriptase inhibitors (e.g., Nevirapine) or other specifically excluded prior
medications, if received without complications for at least 4 weeks prior to study
Patients must have:
- Serologically documented HIV infection.
- Single-dose patients:
- CD4 cell count greater than 50 (no upper limit for single-dose cohorts).
- CD4 count from 50 to 500 within 35 days prior to entrance on study.
- No active opportunistic infection.
Allowed for entry onto multiple-dose study:
- Single-dose portion of S-1153 study, provided all study visits and evaluations are
completed, all eligibility criteria are met, and a minimum of 30 days has elapsed
before Day 1 of the repeated-dose administration.
Patients with the following symptoms or conditions are excluded:
Active opportunistic infection.
Concomitant use (within 5 half-lives prior to administration and for at least 24 hours
following cessation of treatment with S-1153) of highly plasma-bound drugs with narrow
therapeutic indices, including but not limited to coumadin and dilantin.
1. Investigational new drugs.
- Excluded within 30 days prior to study entry:
- Chronic (greater than 7 days) use of drugs known to affect or be extensively
metabolized by cytochromes P450, including but not limited to ketoconazole,
fluconazole, itraconazole, isoniazid, rifampin, rifabutin, astemizole, terfenadine,
or protease inhibitors.
Excluded within 3 weeks prior to study entry:
- Cytotoxic chemotherapy.
- Interferon treatment.
- Radiation therapy.